English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Epigenetic modifications are involved in breast carcinogenesis. Identifying genes that are epigenetically silenced via methylation could select target patients for diagnostic as well as therapeutic potential. We assessed promoter methylation of breast cancer susceptibility gene 1 ( BRCA1 ) and 17 Beta Hydroxysteroid Dehydrogenase Type 1 ( 17βHSD-1 ) in normal and cancer breast tissues of forty sporadic breast cancer (BC) cases using restriction enzyme based methylation-specific PCR (REMS-PCR). In cancerous tissues,  BRCA1  and  17βHSD-1  were methylated in 42.5% and 97.5%, respectively, while normal tissues had 35% and 95% methylation, respectively.  BRCA1  methylation in normal tissues was 12.2-fold more likely to associate with methylation in cancer tissues ( p  < 0.001). It correlated significantly with increased age at menopause, mitosis, the negative status of Her2, and the molecular subtype “luminal A” ( p  = 0.048,  p  = 0.042,  p  = 0.007, and  p  = 0.049, resp.). Methylation of  BRCA1  and  17βHSD-1  related to luminal A subtype of breast cancer. Since a small proportion of normal breast epithelial cells had  BRCA1  methylation, our preliminary findings suggest that methylation of  BRCA1  may be involved in breast tumors initiation and progression; therefore, it could be used as a biomarker for the early detection of sporadic breast cancer. Methylation of  17βHSD-1  in normal and cancer tissue could save patients the long term use of adjuvant antiestrogen therapies.

international journal of breast cancer

Promoter Methylation Status of Breast Cancer Susceptibility Gene 1 and 17 Beta Hydroxysteroid Dehydrogenase Type 1 Gene in Sporadic Breast Cancer Patients